Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients.
暂无分享,去创建一个
J. Canon | J. Vansteenkiste | Yali Fu | P. Vuylsteke | T. Morán | M. Graas | D. Massey | J. Greve | D. Galdermans | V. Chand | J. Grève